OLMA Olema Pharmaceuticals, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Clinical-stage biopharma developing next-generation targeted therapies for ER+ breast cancer, emphasizing oral small molecule endocrine therapies
• • New emphasis: Initiated pivotal Phase 3 OPERA-01 trial for palazestrant monotherapy (2023) and Phase 3 OPERA-02 trial with ribociclib combination (2025)
• • Strategic shift: Collaboration with Novartis for ribociclib supply, advancing palazestrant as potential endocrine therapy of choice in frontline metastatic breast cancer
• • Quantitative highlight: Over 400 patients treated with palazestrant; FDA Fast Track designation granted in July 2022
• • Noteworthy: Second product OP-3136 entered clinical development in late 2024 targeting KAT6, with IND clearance and ongoing Phase 1 trial enrollment

Risk Factors

• • FDA regulatory risk: reliance on successful OPERA-01 Phase 3 trial results expected fall 2026 for NDA submission and potential FDA approval by late 2027
• • Geopolitical/macroeconomic threat: funding and operational risks tied to global economic uncertainty and volatile credit markets impacting capital raises and collaborations
• • Supply chain vulnerability: dependence on third-party contract manufacturers (CMOs) for clinical and potential commercial production with no in-house manufacturing
• • Competitive risk: Novartis collaboration supplying ribociclib for OPERA-02 trial, with palazestrant competing against established CDK4/6 inhibitors like palbociclib and ribociclib
• • Financial risk: accumulated deficit $597.6 million with net losses increasing to $162.5 million in 2025, requiring ongoing substantial capital raises including $237 million net from 2024 private placement

Management Discussion & Analysis

• • Revenue and profitability details not disclosed in the provided MD&A excerpt
• • No segment performance data available in the provided text
• • Cash flow, capital allocation, buybacks, dividends, and capex information not included
• • Forward-looking statements indicating potential risks and uncertainties affecting actual results and events timing

What are the latest OLMA SEC filings in 2026?

Olema Pharmaceuticals, Inc. (OLMA) has filed a 10-K annual report on March 16, 2026, a 10-Q quarterly report on May 12, 2026, an 8-K current report on June 23, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did OLMA file its most recent 10-K annual report?

Olema Pharmaceuticals, Inc. (OLMA) filed its most recent 10-K annual report on March 16, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view OLMA 10-Q quarterly reports?

Olema Pharmaceuticals, Inc. (OLMA)'s most recent 10-Q quarterly report was filed on May 12, 2026. SignalX displays every OLMA 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has OLMA filed recently?

Olema Pharmaceuticals, Inc. (OLMA)'s most recent 8-K was filed on June 23, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find OLMA insider trading activity (Form 4)?

SignalX aggregates every OLMA Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does OLMA file with the SEC?

Olema Pharmaceuticals, Inc. (OLMA) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new OLMA filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Olema Pharmaceuticals, Inc. (OLMA).

What is OLMA's SEC CIK number?

Olema Pharmaceuticals, Inc. (OLMA)'s SEC CIK (Central Index Key) number is 1750284. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1750284 to look up all OLMA filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find OLMA return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Olema Pharmaceuticals, Inc. (OLMA) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.